High prevalence of HER-2/neu overexpression in female breast cancer among an Iraqi population exposed to depleted uranium
- PMID: 19008567
- PMCID: PMC2669727
- DOI: 10.4103/1477-3163.44026
High prevalence of HER-2/neu overexpression in female breast cancer among an Iraqi population exposed to depleted uranium
Abstract
Background: This study aimed to estimate the rate of HER-2/neu (c-erbB2) immunohistochemical overexpression in different histological types of breast cancer found in the middle Euphrates region of Iraq, a region that was exposed to high levels of depleted uranium. HER-2/neu (c-erbB2) overexpression was correlated with common clinicopathological parameters such as age, grade, stage, tumor size and lymph node involvement to determine if any particular biomarker for exposure to depleted uranium could be found in the tumor samples from this region.
Materials and methods: The present investigation was performed over a period starting from September 2007 to June 2008. Formalin-fixed, paraffin-embedded blocks from 90 patients with breast cancer were included in this study. A group of 25 patients with benign breast lesions (fibroadenoma) was included as a comparative group, and 20 breast tissue sections were used as controls. Labeled streptavidin-biotin (LSAB) complex method was employed for immunohistochemical detection of HER-2/neu.
Results: HER-2/neu immuno-expression was positive in 67.8% of breast cancer, while it was negative in all benign breast lesions (fibroadenoma) ( P P P > 0.05).
Conclusion: Based upon the findings of this study, it can be concluded that HER-2/neu overexpression plays an important role in the pathogenesis of breast cancer and is associated with a worse prognosis. The findings indicate that in regions exposed to high levels of depleted uranium, HER-2/neu overexpression is high, but its correlation with age, grade, stage, tumor size, and lymph node involvement is similar to studies that have been conducted on populations not exposed to depleted uranium.
Figures

Similar articles
-
Exposure to depleted uranium does not alter the co-expression of HER-2/neu and p53 in breast cancer patients.BMC Res Notes. 2011 Mar 29;4:87. doi: 10.1186/1756-0500-4-87. BMC Res Notes. 2011. PMID: 21443808 Free PMC article.
-
Expression of VEGF in urinary bladder transitional cell carcinoma in an Iraqi population subjected to depleted uranium: an immunohistochemical study.Appl Immunohistochem Mol Morphol. 2009 Jul;17(4):307-11. doi: 10.1097/PAI.0b013e3181941794. Appl Immunohistochem Mol Morphol. 2009. PMID: 19151604
-
Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.Cancer Res. 1993 Oct 15;53(20):4960-70. Cancer Res. 1993. PMID: 8104689
-
Immunohistochemical COX-2 overexpression correlates with HER-2/neu overexpression in invasive breast carcinomas: a pilot study.Pathol Res Pract. 2011 Mar 15;207(3):182-7. doi: 10.1016/j.prp.2011.01.005. Epub 2011 Mar 2. Pathol Res Pract. 2011. PMID: 21371829
-
Quantitation of HER-2/neu oncoprotein overexpression in invasive breast cancer by image analysis: a study comparing fresh and paraffin-embedded material.Anal Cell Pathol. 1991 Jul;3(4):195-202. Anal Cell Pathol. 1991. PMID: 1679345
Cited by
-
Increased PTEN gene expression in patients with endometrial carcinoma from areas of high risk depleted uranium exposure.BMC Res Notes. 2019 Oct 29;12(1):708. doi: 10.1186/s13104-019-4756-4. BMC Res Notes. 2019. PMID: 31665075 Free PMC article.
-
Incidence of haematological malignancies in Kosovo-A post "uranium war" concern.PLoS One. 2020 May 4;15(5):e0232063. doi: 10.1371/journal.pone.0232063. eCollection 2020. PLoS One. 2020. PMID: 32365107 Free PMC article.
-
Comparing the metal concentration in the hair of cancer patients and healthy people living in the malwa region of punjab, India.Clin Med Insights Oncol. 2014 Jan 9;8:1-13. doi: 10.4137/CMO.S13410. eCollection 2014 Jan 9. Clin Med Insights Oncol. 2014. PMID: 24453505 Free PMC article.
-
Specific-mutational patterns of p53 gene in bladder transitional cell carcinoma among a group of Iraqi patients exposed to war environmental hazards.BMC Res Notes. 2012 Aug 28;5:466. doi: 10.1186/1756-0500-5-466. BMC Res Notes. 2012. PMID: 22929185 Free PMC article.
-
HER2 status in breast cancer: experience of a Spanish National Reference Centre.Clin Transl Oncol. 2011 May;13(5):335-40. doi: 10.1007/s12094-011-0663-4. Clin Transl Oncol. 2011. PMID: 21596662
References
-
- Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94:153–6. - PubMed
-
- Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000;21:3651–64. - PubMed
-
- Hung MC, Lau YK. Basic science of HER-2/neu: A review. Semin Oncol. 1999;26:51–9. - PubMed
-
- Coussens L, Yang-Feng TL, Lioa YC, Chen E, Gray A, McGrath J, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985;230:1132–9. - PubMed
-
- Schecter AL, Stern DF, Vaidyanathan L, Decker S, Drebin JA, Greene MI, et al. The neu oncogene: An erbB-related gene encoding a 185,000-Mr tumor antigen. Nature. 1984;312:513–6. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous